Related Experiment Video
Updated: Sep 30, 2025
08:35
A Simple and Inexpensive Method for Determining Cold Sensitivity and Adaptation in Mice
Published on: March 17, 2015
15.1K
β-Lactam TRPM8 Antagonist RGM8-51 Displays Antinociceptive Activity in Different Animal Models
Cristina Martín-Escura1,2, Alicia Medina-Peris3, Luke A Spear1
1Instituto de Química Médica (IQM-CSIC), 28006 Madrid, Spain.
International Journal of Molecular Sciences
|March 10, 2022
Summary
A novel beta-lactam derivative, RGM8-51, acts as a Transient Receptor Potential Melastatin Subtype 8 (TRPM8) antagonist. This compound demonstrates significant pain relief in preclinical models of neuropathy and hyperesthesia.
Area of Science:
- Neuroscience
- Pharmacology
- Pain Research
Background:
- Transient Receptor Potential Melastatin Subtype 8 (TRPM8) channels are key players in sensory neurons and pain pathways.
- The therapeutic potential of TRPM8 modulators for pain management remains debated due to varied outcomes across different pain models.
Purpose of the Study:
- To evaluate the antinociceptive properties of a novel beta-lactam derivative, RGM8-51, as a TRPM8 antagonist.
- To assess the selectivity of RGM8-51 against related thermoTRP channels and other pain receptors.
Main Methods:
- In vitro assessment of RGM8-51's effect on menthol-evoked neuronal firing in rat dorsal root ganglion (DRG) neurons.
- In vivo evaluation of RGM8-51's antinociceptive activity in mouse models of oxaliplatin-induced peripheral neuropathy and NTG-induced hyperesthesia.
- Assessment of RGM8-51's efficacy in a rat model of neuropathic pain induced by chronic sciatic nerve constriction.
Main Results:
- RGM8-51 effectively inhibited menthol-evoked neuronal activity in DRG neurons without impacting essential ion conductances.
- The compound demonstrated in vivo antinociceptive effects against cold stimuli in a chemotherapy-induced neuropathy model.
- RGM8-51 alleviated cold, mechanical, and heat hypersensitivity in neuropathic pain models and mechanical hypersensitivity in a hyperesthesia model.
Conclusions:
- RGM8-51 exhibits potent TRPM8 antagonist activity and selectivity.
- Preclinical data support RGM8-51 as a promising pharmacological agent for investigating TRPM8-associated pain conditions.
Related Concept Videos
01:25Analgesia and Pain Management
861
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
861
01:44Nociception
30.0K
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain.
30.0K